-
Je něco špatně v tomto záznamu ?
Growth Differentiation Factor-15 Is Associated With Congestion-Related Anorexia and Weight Loss in Advanced Heart Failure
L. Monzo, P. Jarolim, BA. Borlaug, J. Benes, I. Jurcova, D. Jenca, K. Kroupova, P. Wohlfahrt, M. Kotrc, V. Melenovsky
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, pozorovací studie
- MeSH
- hmotnostní úbytek * MeSH
- kachexie * etiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nechutenství * etiologie MeSH
- retrospektivní studie MeSH
- růstový diferenciační faktor 15 * krev MeSH
- senioři MeSH
- srdeční selhání * komplikace patofyziologie krev MeSH
- tepový objem fyziologie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
BACKGROUND: Growth differentiation factor (GDF)-15 is a pleiotropic cytokine that is associated with appetite-suppressing effects and weight loss in patients with malignancy. OBJECTIVES: This study aims to investigate the relationships between GDF-15 levels, anorexia, cachexia, and clinical outcomes in patients with advanced heart failure with reduced ejection fraction (HFrEF). METHODS: In this observational, retrospective analysis, a total of 344 patients with advanced HFrEF (age 58 ± 10 years, 85% male, 67% NYHA functional class III), underwent clinical and echocardiographic examination, body composition evaluation by skinfolds and dual-energy x-ray absorptiometry, circulating metabolite assessment, Minnesota Living with Heart Failure Questionnaire, and right heart catheterization. RESULTS: The median GDF-15 level was 1,503 ng/L (Q1-Q3: 955-2,332 ng/L) (reference range: <1,200 ng/L). Higher GDF-15 levels were associated with more prevalent anorexia and cachexia. Patients with higher GDF-15 had increased circulating free fatty acids and beta-hydroxybutyrate, lower albumin, cholesterol, and insulin/glucagon ratio, consistent with a catabolic state. Patients with higher GDF-15 had worse congestion and more severe right ventricular dysfunction. In multivariable Cox analysis, elevated GDF-15 was independently associated with risk of the combined endpoint of death, urgent transplantation, or left ventricular assist device implantation, even after adjusting for coexisting anorexia and cachexia (T3 vs T1 HR: 2.31 [95% CI: 1.47-3.66]; P < 0.001). CONCLUSIONS: In patients with advanced HFrEF, elevated circulating GDF-15 levels are associated with a higher prevalence of anorexia and cachexia, right ventricular dysfunction, and congestion, as well as an independently increased risk of adverse events. Further studies are warranted to determine whether therapies altering GDF-15 signaling pathways can affect metabolic status and clinical outcomes in advanced HFrEF.
Department of Cardiovascular Diseases Mayo Clinic Rochester Minnesota USA
Institute for Clinical and Experimental Medicine Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25010036
- 003
- CZ-PrNML
- 005
- 20250429135349.0
- 007
- ta
- 008
- 250415s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jchf.2024.10.023 $2 doi
- 035 __
- $a (PubMed)39797849
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Monzo, Luca $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic; Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, Inserm U1116, CHRU de Nancy and F-CRIN INI-CRCT, Nancy, France
- 245 10
- $a Growth Differentiation Factor-15 Is Associated With Congestion-Related Anorexia and Weight Loss in Advanced Heart Failure / $c L. Monzo, P. Jarolim, BA. Borlaug, J. Benes, I. Jurcova, D. Jenca, K. Kroupova, P. Wohlfahrt, M. Kotrc, V. Melenovsky
- 520 9_
- $a BACKGROUND: Growth differentiation factor (GDF)-15 is a pleiotropic cytokine that is associated with appetite-suppressing effects and weight loss in patients with malignancy. OBJECTIVES: This study aims to investigate the relationships between GDF-15 levels, anorexia, cachexia, and clinical outcomes in patients with advanced heart failure with reduced ejection fraction (HFrEF). METHODS: In this observational, retrospective analysis, a total of 344 patients with advanced HFrEF (age 58 ± 10 years, 85% male, 67% NYHA functional class III), underwent clinical and echocardiographic examination, body composition evaluation by skinfolds and dual-energy x-ray absorptiometry, circulating metabolite assessment, Minnesota Living with Heart Failure Questionnaire, and right heart catheterization. RESULTS: The median GDF-15 level was 1,503 ng/L (Q1-Q3: 955-2,332 ng/L) (reference range: <1,200 ng/L). Higher GDF-15 levels were associated with more prevalent anorexia and cachexia. Patients with higher GDF-15 had increased circulating free fatty acids and beta-hydroxybutyrate, lower albumin, cholesterol, and insulin/glucagon ratio, consistent with a catabolic state. Patients with higher GDF-15 had worse congestion and more severe right ventricular dysfunction. In multivariable Cox analysis, elevated GDF-15 was independently associated with risk of the combined endpoint of death, urgent transplantation, or left ventricular assist device implantation, even after adjusting for coexisting anorexia and cachexia (T3 vs T1 HR: 2.31 [95% CI: 1.47-3.66]; P < 0.001). CONCLUSIONS: In patients with advanced HFrEF, elevated circulating GDF-15 levels are associated with a higher prevalence of anorexia and cachexia, right ventricular dysfunction, and congestion, as well as an independently increased risk of adverse events. Further studies are warranted to determine whether therapies altering GDF-15 signaling pathways can affect metabolic status and clinical outcomes in advanced HFrEF.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a růstový diferenciační faktor 15 $x krev $7 D055436
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a srdeční selhání $x komplikace $x patofyziologie $x krev $7 D006333
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a hmotnostní úbytek $7 D015431
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a nechutenství $x etiologie $7 D000855
- 650 12
- $a kachexie $x etiologie $7 D002100
- 650 _2
- $a tepový objem $x fyziologie $7 D013318
- 650 _2
- $a senioři $7 D000368
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Jarolim, Petr $u Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Department of Pathology, Boston, Massachusetts, USA
- 700 1_
- $a Borlaug, Barry A $u Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA
- 700 1_
- $a Benes, Jan $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
- 700 1_
- $a Jurcova, Ivana $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
- 700 1_
- $a Jenca, Dominik $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
- 700 1_
- $a Kroupova, Katerina $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
- 700 1_
- $a Wohlfahrt, Peter $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
- 700 1_
- $a Kotrc, Martin $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
- 700 1_
- $a Melenovsky, Vojtech $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic. Electronic address: vome@ikem.cz
- 773 0_
- $w MED00184931 $t JACC. Heart failure $x 2213-1787 $g Roč. 13, č. 2 (2025), s. 315-329
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39797849 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429135344 $b ABA008
- 999 __
- $a ok $b bmc $g 2311417 $s 1247117
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 13 $c 2 $d 315-329 $e 20250108 $i 2213-1787 $m JACC. Heart failure $n JACC Heart Fail $x MED00184931
- LZP __
- $a Pubmed-20250415